Abstract
Renal transplantation is the treatment of choice for end-stage renal disease in children, leading to substantial improvement in the quality of life. However, despite a significant improvement in short-term results, important long-term problems remain unsolved. Allograft half-life has only slightly improved in pediatric renal transplant recipients during the last decade due to the lack of effective treatment for chronic rejection, frequent recipient non-compliance, particularly in adolescence, and nephrotoxicity of the immunosuppressive calcineurin inhibitors cyclosporine A and tacrolimus. Therefore, a pediatric renal graft recipient is likely to need several retransplantations during his life. Furthermore, the immunosuppressive drugs used today have potentially serious side effects, including infection, nephrotoxicity and de novo malignancy. These topics are particularly relevant for children who are likely to receive immuno-suppressive therapy for several decades. The biological differences between an adult and a growing and developing pediatric transplant recipient also have to be taken into account. It is important, therefore, to develop immunosup-pressive protocols that are adjusted to the specific needs of a growing child.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Mason J. The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr. Nephrol. 1990; 4: 554–574.
Novick AC, Ho-Hsieh H, Steinmuller DS et al. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation: Results of randomized prospective trial. Transplantation. 1986; 42: 154–158.
Laine J, Holmberg C. Renal and adrenal mechanisms in cyclosporine induced hyperkalemia after renal transplantation. Eur. J. Clin. Invest. 1995; 25: 670–676.
Laine J, Holmberg C. Mechanisms of hyperuricemia renal transplanted children. Nephron. 1996; 74: 318–323.
Kahan BD. Drug therapy: cyclosporine. N. Engl. J. Med. 1989; 321: 1725–1738.
Cho WY, Terasaki PI, Graver B. Fifteen-year kidney graft survival. In: Terasaki PI (ed.) Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory: 1989; 325–331.
Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: an obliterative micro-vascular injury. J. Am. Soc. Nephrol. 1991; 2(2 Suppl 1): S45–S52.
European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994; 344: 423–428.
The US Multicenter Liver FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N. Engl. J. Med. 1994; 331: 1110–1115.
Porayko MK, Texton SC, Krom RA et al. Nephrotoxic effects of primary immunosuppression with FK 506 and cyclosporine regimens after liver transplantation. Mayo. Clin. Proc. 1994; 69: 105–111.
Holman MJ, Gonwa TA, Cooper B et al. FK506-associated thrombotic thrombocytopenic purpura. Transplantation. 1993; 55: 205–206.
Ruggenenti P, Perico N, Mosconi L et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int. 1993; 43: 706–711.
Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL. Pharmacokinetically determined cyclosporin dosage in young children. Pediatr. Nephrol. 1991; 5: 1–4.
Tejani A, Sullivan EK. Higher maintenance cyclosporine dose decreases the risk of graft failure in North American children: a report of the North American Pediatric Renal Transplant Cooperative Study. J. Am. Soc. Nephrol. 1996; 7: 550–555.
Chrysostomou A, Walker RG, Russ GR et al. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation. 1993; 55: 300–304.
Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int. 1993; 43: 419–425.
Houde I, Noel R, Cotret PR et al. Prednisone-mycophenolate mofetil double therapy for cyclosporine A toxicity in kidney transplantation. Transplantation. 1998; Suppl 139: abstract 243.
Ducloux D, Fournier V, Bresson-Vautrin C et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity. Transplantation. 1998; 65: 1504–1506.
Sheil A. Cancer in dialysis and transplant patients. In: Morris P (ed.) Kidney Transplantation: Principles and Practice, 4th edn. Philadelphia: WB Saunders; 1994: 390–400.
Penn I. The problem of cancer in organ transplant recipients: an overview. Transplant. Sci. 1994; 4: 23–32.
Penn I. The changing patterns of posttransplant malignancies. Transplant. Proc. 1991; 23: 1101–1103.
Penn I. Cancers complicating organ transplantation. N. Engl. J. Med. 1990; 323: 1767–1769.
McEnery P, Stablein P, Arbus G, Tejani A. Renal transplantation in children. A report of the North American Pediatric Renal transplant Cooperative Study. N. Engl. J. Med. 1992; 326: 1727–1732.
Tejani A, Sullivan EK, Alexander S, Fine R, Harmon W, Lilienfeld D. Post-transplant deaths and factors that influence the mortality rate in North American children. Transplantation. 1994; 57: 547–553.
Mullen DL, Silberg SG, Penn I, Hammond WS. Squamous cell carcinoma of the skin and lip in renal homograft recipients. Cancer. 1976; 37: 729–734.
Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998; 351: 623–628.
Ho M, Jaffe R, Miller G et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestation in children. Transplantation. 1988; 45: 719–724.
Opelz G, Henderson R, for the Collaborative Transplant Study. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993; 342: 1514–1516.
Conlon PJ, Smith SR. Transmission of cancer with cadaveric donor organs. J. Am. Soc. Nephrol. 1995; 6: 54–60.
Gupta AK, Cardella CJ, Haberman HE Cutaneous malignant neoplasms in patients with renal transplants. Arch. Dermatol. 1986; 122: 1288–1293.
Halmos O, Inturri P, Galligioni A et al. Two cases of Kaposi’s sarcoma in renal and live transplant recipients treated with interferon. Clin. Transplant. 1996; 10: 374–378.
Tönshoff B, Mehls O. Interactions between glucocorticoids and the growth hormone - insulin-like growth factor axis. Pediatr. Transplant. 1997; 1: 183–188.
Tönshoff B, Mehls O. Factors affecting growth and strategies for treatment in children after renal transplantation. Pediatr. Transplant. 1997; 1: 176–182.
Tejani AH, Fine RN, Alexander S et al. Factors predictive of sustained growth in children after renal transplantation. J. Pediatr. 1993; 122: 397–402.
Hokken-Koelega ACS, van Zaal AE, de Ridder MAJ et al. Growth after renal transplantation in prepubertal children: impact of various treatment modalities. Pediatr. Res. 1994; 3: 367–371.
Broyer M, Guest G, Gagnadoux M-E Growth rate in children receiving alternate-day cortico steroid treatment after kidney transplantation. J. Pediatr. 1992; 120: 721–725.
Jabs K, Sullivan EK, Avner ED, Harmon WE. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. Transplantation. 1996; 61: 31–36.
Klare B, Strom TM, Hahn H et al. Remarkable long-term prognosis and excellent growth in kidney-transplant children under cyclosporine monotherapy. Transplant. Proc. 1991; 23: 1013–1017.
Ingulli E, Tejani AH. Steroid withdrawal after renal transplantation. In: Tejani AH, Fine RN (eds). Pediatric Renal Transplantation. New York: Wiley Liss, 1994; 221–238.
Shapiro R, Scantlebury VP, Jordan ML et al. FK 506 in pediatric kidney transplantation-Primary and rescue experience. Pediatr. Nephrol. 1995; 9: 43–48.
Grinyo JM, Gil-Vernet S, Seron D et al. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation. 1997; 63: 1688–1690.
Tönshoff B, Mehls O. Use of rhGH post transplant in children. In: Tejani AH, Fine RN (eds). Pediatric Renal Transplantation. New York: Wiley & Sons, 1994; 441–460.
Tönshoff B, Haffner D, Mehls O et al. Efficacy and safety of growth hormone treatment in short children with renal allografts: three year experience. Kidney. Int. 1993; 44: 199–207.
Guest G, Berard E, Crosnier H, Chevallier T, Rappaport R, Broyer M. Effects of growth hormone in short children after renal transplantation. French Society of Pediatric Nephrology. Pediatr. Nephrol. 1998; 12: 437–446.
Tönshoff B. Editorial: The current status of mycophenolate mofetil in pediatric renal transplantation. Pediatr. Transplant. 1999, in press.
Editor information
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Tönshoff, B., Mehls, O., Weber, L. (1999). Can we minimize the long-term side effects of immunosuppressive drugs in pediatric patients?. In: Cochat, P., Traeger, J., Merieux, C., Derchavane, M. (eds) Immunosuppression under Trial. Transplantation and Clinical Immunology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4643-2_14
Download citation
DOI: https://doi.org/10.1007/978-94-011-4643-2_14
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5960-2
Online ISBN: 978-94-011-4643-2
eBook Packages: Springer Book Archive